Safety of VivaGel® in Young Women
Author Information
Author(s): Cohen Craig R., Brown Joelle, Moscicki Anna-Barbara, Bukusi Elizabeth A., Paull Jeremy R. A., Price Clare F., Shiboski Stephen
Primary Institution: University of California San Francisco
Hypothesis
To assess the safety of VivaGel® used vaginally twice daily for 14 days among healthy, sexually-abstinent women, aged 18–24 years in the USA and Kenya.
Conclusion
GU adverse events and colposcopic findings consistent with mild epithelial irritation and inflammation occurred more commonly among women in the VivaGel arm.
Supporting Evidence
- 83% of participants in the VivaGel arm experienced at least one grade 1 or 2 GU adverse event.
- No grade 3 or 4 adverse events occurred during the trial.
- Colposcopic findings were significantly more common in the VivaGel arm compared to placebo.
Takeaway
The study tested a gel called VivaGel® to see if it was safe for young women to use. Some women had mild irritation, but it was mostly safe.
Methodology
Participants were randomized 2:1 to receive either VivaGel or placebo, and safety was assessed by comparing adverse events and colposcopy findings.
Potential Biases
Potential bias due to differences in participant demographics and adherence rates between sites.
Limitations
The study was closed before reaching the planned sample size of 60 participants.
Participant Demographics
Healthy, sexually-abstinent women aged 18-24 from the USA and Kenya.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 0.8-2.2
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website